These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1664829)

  • 21. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
    Vallée E; Azoulay-Dupuis E; Bauchet J; Pocidalo JJ
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1203-8. PubMed ID: 1326627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
    Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():226-7. PubMed ID: 8549311
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():228-9. PubMed ID: 8549312
    [No Abstract]   [Full Text] [Related]  

  • 28. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone.
    Nakanishi N; Inoue M; Inoue K; Yamaguchi T; Mitsuhashi S
    Chemotherapy; 1990; 36(5):345-55. PubMed ID: 2209168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
    Pattyn SR
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):613-7. PubMed ID: 1666402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.
    Van Caekenberghe D
    J Antimicrob Chemother; 1990 Sep; 26(3):381-6. PubMed ID: 2228828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
    Zabinski RA; Vance-Bryan K; Krinke AJ; Walker KJ; Moody JA; Rotschafer JC
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2454-8. PubMed ID: 8285633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    J Antimicrob Chemother; 1994 Dec; 34(6):875-83. PubMed ID: 7730231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Rubinstein E
    J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Will pneumococci put quinolones in their place?
    Legg JM; Bint AJ
    J Antimicrob Chemother; 1999 Oct; 44(4):425-7. PubMed ID: 10588301
    [No Abstract]   [Full Text] [Related]  

  • 39. A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections.
    Kosmidis J
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():73-9. PubMed ID: 1664832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.
    Fukuda Y; Yanagihara K; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Mizuta Y; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2006 Jan; 50(1):121-5. PubMed ID: 16377676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.